ES3014965T3 - Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy - Google Patents
Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy Download PDFInfo
- Publication number
- ES3014965T3 ES3014965T3 ES22753953T ES22753953T ES3014965T3 ES 3014965 T3 ES3014965 T3 ES 3014965T3 ES 22753953 T ES22753953 T ES 22753953T ES 22753953 T ES22753953 T ES 22753953T ES 3014965 T3 ES3014965 T3 ES 3014965T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- pharmaceutically acceptable
- lvef
- acceptable salt
- biplane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203333P | 2021-07-16 | 2021-07-16 | |
| US202263299753P | 2022-01-14 | 2022-01-14 | |
| US202263305609P | 2022-02-01 | 2022-02-01 | |
| US202263331197P | 2022-04-14 | 2022-04-14 | |
| US202263343975P | 2022-05-19 | 2022-05-19 | |
| PCT/US2022/073808 WO2023288324A1 (en) | 2021-07-16 | 2022-07-15 | Methods for treating hypertrophic cardiomyopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3014965T3 true ES3014965T3 (en) | 2025-04-28 |
Family
ID=82850823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22753953T Active ES3014965T3 (en) | 2021-07-16 | 2022-07-15 | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20230058927A1 (enExample) |
| EP (2) | EP4370116B1 (enExample) |
| JP (1) | JP2024526334A (enExample) |
| KR (1) | KR20240047359A (enExample) |
| AU (1) | AU2022312506A1 (enExample) |
| CA (1) | CA3225787A1 (enExample) |
| CL (2) | CL2024000090A1 (enExample) |
| DK (1) | DK4370116T3 (enExample) |
| ES (1) | ES3014965T3 (enExample) |
| FI (1) | FI4370116T3 (enExample) |
| HR (1) | HRP20250174T1 (enExample) |
| HU (1) | HUE070699T2 (enExample) |
| IL (1) | IL310140A (enExample) |
| LT (1) | LT4370116T (enExample) |
| MX (1) | MX2024000804A (enExample) |
| PL (1) | PL4370116T3 (enExample) |
| PT (1) | PT4370116T (enExample) |
| RS (1) | RS66640B1 (enExample) |
| SI (1) | SI4370116T1 (enExample) |
| SM (1) | SMT202500098T1 (enExample) |
| TW (1) | TW202320763A (enExample) |
| WO (1) | WO2023288324A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006296YA (en) | 2018-01-19 | 2020-08-28 | Cytokinetics Inc | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| MX2022000498A (es) | 2019-07-17 | 2022-02-03 | Cytokinetics Inc | Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida. |
| EP4370116B1 (en) * | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| JP2025525913A (ja) * | 2022-08-04 | 2025-08-07 | サイトキネティックス， インコーポレイテッド | 閉塞性肥大型心筋症を治療するための方法 |
| WO2024182469A1 (en) * | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
| CN120712262A (zh) * | 2023-03-02 | 2025-09-26 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| WO2025198687A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
| IL322175A (en) * | 2017-08-04 | 2025-09-01 | Myokardia Inc | Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds |
| SG11202006296YA (en) * | 2018-01-19 | 2020-08-28 | Cytokinetics Inc | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| WO2020257609A1 (en) | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| WO2021011808A1 (en) | 2019-07-17 | 2021-01-21 | Cytokinetics, Inc. | Cardiac sarcomere inhibitor oral formulations |
| LT3999180T (lt) | 2019-07-17 | 2024-08-26 | Cytokinetics, Inc. | (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai |
| CA3157629A1 (en) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| KR20230079053A (ko) | 2020-08-28 | 2023-06-05 | 미요카디아, 인크. | 미오신 조절제를 이용한 치료 방법 |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| EP4249474A4 (en) | 2020-11-20 | 2024-04-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Triazine dione derivative, preparation method therefor and application thereof in medicine |
| CN116507621B (zh) | 2020-11-24 | 2025-10-17 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| EP4370116B1 (en) | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| JP2024530111A (ja) | 2021-08-03 | 2024-08-16 | サイトキネティックス， インコーポレイテッド | アフィカムテンを調製するための工程 |
| CN119789856A (zh) | 2022-04-26 | 2025-04-08 | 迈奥卡迪亚公司 | 施用肌球蛋白抑制剂的方法 |
| US20240091203A1 (en) | 2022-07-20 | 2024-03-21 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| JP2025525913A (ja) | 2022-08-04 | 2025-08-07 | サイトキネティックス， インコーポレイテッド | 閉塞性肥大型心筋症を治療するための方法 |
| WO2024050139A1 (en) | 2022-09-02 | 2024-03-07 | AnaBios Corporation | Therapeutic uses of cardiac myosin inhibitors |
| EP4604841A1 (en) | 2022-10-21 | 2025-08-27 | Prolaio, Inc. | System and method of treatment of hypertrophic cardiomyopathy |
| WO2024097284A1 (en) | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| EP4666076A1 (en) | 2023-02-17 | 2025-12-24 | Bristol-Myers Squibb Company | Methods of prognosis and treatment for heart failure with preserved ejection fraction using urinary protein levels |
| WO2024182469A1 (en) | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
| CN120712262A (zh) | 2023-03-02 | 2025-09-26 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| CN122070481A (zh) | 2023-11-01 | 2026-05-19 | 百时美施贵宝公司 | 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法 |
-
2022
- 2022-07-15 EP EP22753953.3A patent/EP4370116B1/en active Active
- 2022-07-15 RS RS20250239A patent/RS66640B1/sr unknown
- 2022-07-15 WO PCT/US2022/073808 patent/WO2023288324A1/en not_active Ceased
- 2022-07-15 CA CA3225787A patent/CA3225787A1/en active Pending
- 2022-07-15 HR HRP20250174TT patent/HRP20250174T1/hr unknown
- 2022-07-15 MX MX2024000804A patent/MX2024000804A/es unknown
- 2022-07-15 PL PL22753953.3T patent/PL4370116T3/pl unknown
- 2022-07-15 DK DK22753953.3T patent/DK4370116T3/da active
- 2022-07-15 SI SI202230095T patent/SI4370116T1/sl unknown
- 2022-07-15 AU AU2022312506A patent/AU2022312506A1/en active Pending
- 2022-07-15 PT PT227539533T patent/PT4370116T/pt unknown
- 2022-07-15 HU HUE22753953A patent/HUE070699T2/hu unknown
- 2022-07-15 KR KR1020247002855A patent/KR20240047359A/ko active Pending
- 2022-07-15 LT LTEPPCT/US2022/073808T patent/LT4370116T/lt unknown
- 2022-07-15 US US17/812,994 patent/US20230058927A1/en not_active Abandoned
- 2022-07-15 FI FIEP22753953.3T patent/FI4370116T3/fi active
- 2022-07-15 ES ES22753953T patent/ES3014965T3/es active Active
- 2022-07-15 EP EP25151678.7A patent/EP4548912A3/en active Pending
- 2022-07-15 SM SM20250098T patent/SMT202500098T1/it unknown
- 2022-07-15 JP JP2024501787A patent/JP2024526334A/ja active Pending
- 2022-07-15 IL IL310140A patent/IL310140A/en unknown
- 2022-07-15 TW TW111126631A patent/TW202320763A/zh unknown
-
2024
- 2024-01-10 CL CL2024000090A patent/CL2024000090A1/es unknown
- 2024-06-25 CL CL2024001945A patent/CL2024001945A1/es unknown
- 2024-10-08 US US18/909,401 patent/US12370179B1/en active Active
- 2024-10-15 US US18/916,215 patent/US20250177357A1/en active Pending
-
2025
- 2025-07-01 US US19/257,352 patent/US20260097021A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240047359A (ko) | 2024-04-12 |
| RS66640B1 (sr) | 2025-04-30 |
| US12370179B1 (en) | 2025-07-29 |
| IL310140A (en) | 2024-03-01 |
| MX2024000804A (es) | 2024-02-06 |
| PL4370116T3 (pl) | 2025-04-28 |
| CA3225787A1 (en) | 2023-01-19 |
| US20260097021A1 (en) | 2026-04-09 |
| HRP20250174T1 (hr) | 2025-04-11 |
| CL2024000090A1 (es) | 2024-08-16 |
| CL2024001945A1 (es) | 2024-12-06 |
| EP4370116A1 (en) | 2024-05-22 |
| US20250177357A1 (en) | 2025-06-05 |
| PT4370116T (pt) | 2025-03-14 |
| EP4370116B1 (en) | 2025-01-15 |
| HUE070699T2 (hu) | 2025-06-28 |
| WO2023288324A1 (en) | 2023-01-19 |
| DK4370116T3 (da) | 2025-02-03 |
| LT4370116T (lt) | 2025-04-10 |
| SI4370116T1 (sl) | 2025-04-30 |
| TW202320763A (zh) | 2023-06-01 |
| SMT202500098T1 (it) | 2025-03-12 |
| EP4548912A2 (en) | 2025-05-07 |
| AU2022312506A1 (en) | 2024-02-01 |
| FI4370116T3 (fi) | 2025-03-04 |
| US20230058927A1 (en) | 2023-02-23 |
| EP4548912A3 (en) | 2025-07-02 |
| JP2024526334A (ja) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4370116B1 (en) | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy | |
| US20240091203A1 (en) | Methods for treating non-obstructive hypertrophic cardiomyopathy | |
| US20240115554A1 (en) | Methods for treating obstructive hypertrophic cardiomyopathy | |
| US12419863B2 (en) | Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy | |
| HK40110429A (en) | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy | |
| HK40110429B (en) | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy | |
| US20160067246A1 (en) | Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy | |
| US20250295639A1 (en) | Methods for treating heart diseases | |
| HK40122886A (en) | Methods for treating non-obstructive hypertrophic cardiomyopathy | |
| HK40105016A (en) | Methods for treating hypertrophic cardiomyopathy | |
| US12551465B2 (en) | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | |
| HK40122885A (en) | Methods for treating obstructive hypertrophic cardiomyopathy | |
| CN117794535A (zh) | 用于治疗肥厚型心肌病的方法 | |
| Hassan et al. | 1. A 50-year-old male with no past medical history of coronary artery disease (CAD) presented to the emergency department with severe retrosternal chest pain. The patient was immediately injected with 25 mCi of Tc-99 m Sestamibi and imaging was performed 3 h later. The gated SPECT dem-onstrated normal wall motion and thickening of the myocardial walls with estimated left ventricu-lar ejection fraction is 57%(normal value is above 50%). The most likely diagnosis is | |
| Gabriel | Medhat Sam Gabriel, Bital Savir-Baruch, Robert H. Wagner, Bruch J. Barron, Davide Bova, Aamna Hassan, Stephanie Rodriguez-Santiago, and Yekaterina Kucerova | |
| Ettachfini et al. | Light-chain cardiac amyloidosis, a condition to consider in daily practice |